tiprankstipranks
Citius Oncology (CTOR)
NASDAQ:CTOR
US Market

Citius Oncology (CTOR) AI Stock Analysis

Compare
73 Followers

Top Page

CT

Citius Oncology

(NASDAQ:CTOR)

46Neutral
Citius Oncology faces significant challenges with poor financial performance characterized by net losses and negative cash flows, indicative of its developmental stage in the pharmaceutical industry. Despite an attractive valuation due to a low P/E ratio, technical analysis suggests bearish trends. The absence of recent earnings call insights or significant corporate events further underscores the high-risk nature of the stock.
Positive Factors
Market Expansion
Citius Oncology plans to expand Lymphir's indications to peripheral T cell lymphoma and broader immune oncology, which presents additional growth opportunities.
Market Readiness
The commercial readiness of Lymphir is underway, with existing therapies generating significant revenues, indicating a receptive market for new treatments.
Negative Factors
Market Competition
Lymphir is targeting the IV-targeted therapy segment of the CTCL market, which usually comes after progression on oral systemics and chemotherapies.

Citius Oncology (CTOR) vs. S&P 500 (SPY)

Citius Oncology Business Overview & Revenue Model

Company DescriptionCitius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
How the Company Makes MoneyCitius Oncology makes money primarily through the development and commercialization of its proprietary oncology treatments. The company generates revenue by licensing its drug candidates to larger pharmaceutical companies, forming partnerships for co-development and commercialization, and through direct sales of approved therapies. Key revenue streams include milestone payments from licensing agreements, royalties from product sales, and research and development funding from strategic partnerships. Additionally, CTOR may receive grants and financial support from government agencies or non-profit organizations dedicated to cancer research.

Citius Oncology Financial Statement Overview

Summary
Citius Oncology's financial performance is characterized by consistent net losses and lack of revenue, reflective of its developmental stage. Balance sheet volatility and negative cash flows highlight financial instability and liquidity challenges, necessitating strategic management.
Income Statement
35
Negative
Citius Oncology shows a challenging income situation with consistent net losses over the reported periods. The absence of revenue and gross profit highlights the early-stage nature or restructuring phase of the company. Despite some improvement in EBIT from 2023 to 2024, the overall profitability metrics remain weak, given the negative net income.
Balance Sheet
45
Neutral
The balance sheet reveals high volatility with fluctuating stockholders' equity and liabilities. Although there is a significant increase in assets from 2023 to 2024, the negative equity in some periods and inconsistent asset base pose stability concerns. The absence of debt could indicate cautious financing, but the negative equity ratios in some periods showcase financial vulnerability.
Cash Flow
40
Negative
Cash flow statements show inconsistent operating cash flows and negative free cash flow, indicating liquidity challenges. The reliance on financing activities to support cash flows is evident, but the lack of consistent positive cash flow from operations could hinder growth prospects. The free cash flow growth rate is negative, which poses a risk for future financial health.
Breakdown
TTMSep 2024Sep 2023Sep 2022
Income StatementTotal Revenue
0.000.000.000.00
Gross Profit
0.000.000.000.00
EBIT
0.00-20.57M-12.12M-4.86M
EBITDA
-6.39M-20.57M-12.12M-4.86M
Net Income Common Stockholders
-6.66M-21.15M-12.70M-5.43M
Balance SheetCash, Cash Equivalents and Short-Term Investments
289.18K112.000.000.00
Total Assets
68.19M84.37M47.73M42.69M
Total Debt
0.003.80M0.000.00
Net Debt
-289.18K3.80M0.000.00
Total Liabilities
31.84K38.23M22.20M6.42M
Stockholders Equity
68.16M46.14M25.54M36.27M
Cash FlowFree Cash Flow
-364.06K-4.87M0.000.00
Operating Cash Flow
-364.06K126.35K0.000.00
Investing Cash Flow
-22.55K-5.00M0.000.00
Financing Cash Flow
353.65K4.87M0.000.00

Citius Oncology Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.86
Price Trends
50DMA
1.02
Negative
100DMA
1.08
Negative
200DMA
4.11
Negative
Market Momentum
MACD
-0.08
Negative
RSI
50.97
Neutral
STOCH
43.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTOR, the sentiment is Neutral. The current price of 0.86 is above the 20-day moving average (MA) of 0.75, below the 50-day MA of 1.02, and below the 200-day MA of 4.11, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 50.97 is Neutral, neither overbought nor oversold. The STOCH value of 43.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CTOR.

Citius Oncology Risk Analysis

Citius Oncology disclosed 51 risk factors in its most recent earnings report. Citius Oncology reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Citius Oncology Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
$14.39B9.818.95%4.37%16.38%-11.64%
46
Neutral
$66.54M3.19-34.78%
46
Neutral
$50.42M-273.36%194.23%45.50%
42
Neutral
$11.01M-151.46%-95.23%-325.89%
41
Neutral
$2.91B-42.88%-17.78%-10.95%
36
Underperform
$31.48M41.08%-0.55%49.85%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CTOR
Citius Oncology
0.80
-10.27
-92.77%
KPTI
Karyopharm Therapeutics
4.06
-15.22
-78.94%
AFMD
Affimed
0.71
-5.95
-89.34%
ADAP
Adaptimmune Therapeutics
0.30
-1.08
-78.26%
MRUS
Merus
43.01
-1.57
-3.52%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.